Skip to content
Advertisement

This Wednesday, Oct. 7, 2020 file photo shows a vial of the Phase 3 Novavax coronavirus vaccine ready for use in a trial at St. George's University hospital in London. The global health agency added Nuvaxovid, also known as NVX-CoV2373, to its emergency use listing following an approval from the European Medicines Agency (EMA). (AP Photo/Alastair Grant, File)

This Wednesday, Oct. 7, 2020 file photo shows a vial of the Phase 3 Novavax coronavirus vaccine ready for use in a trial at St. George's University hospital in London. The global health agency added Nuvaxovid, also known as NVX-CoV2373, to its emergency use listing following an approval from the European Medicines Agency (EMA). (AP Photo/Alastair Grant, File)

Featured Photo Galleries